T1	CHEM 56 65	nivolumab
#1	AnnotatorNotes T1	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T2	CHEM 85 95	ipilimumab
#2	AnnotatorNotes T2	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T3	PROC 102 115	quimioterapia
#3	AnnotatorNotes T3	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T4	PROC 144 157	quimioterapia
#4	AnnotatorNotes T4	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T5	PROC 178 189	tratamiento
#5	AnnotatorNotes T5	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T6	DISO 237 248	metastásico
#6	AnnotatorNotes T6	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T7	PROC 293 330	Estudio fase 3, abierto, aleatorizado
T8	CHEM 335 344	nivolumab
#7	AnnotatorNotes T8	C3657270; nivolumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T9	CHEM 359 369	ipilimumab
#8	AnnotatorNotes T9	C1367202; ipilimumab; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T10	PROC 379 392	quimioterapia
#9	AnnotatorNotes T10	C0392920; Chemotherapy Regimen; Therapeutic or Preventive Procedure | C3665472; Chemotherapy; Therapeutic or Preventive Procedure
T11	DISO 428 444	cáncer urotelial
#10	AnnotatorNotes T11	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
T12	DISO 515 531	Cáncer urotelial
#11	AnnotatorNotes T12	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
T13	DISO 604 620	Cáncer urotelial
#12	AnnotatorNotes T13	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
T14	DISO 697 713	Cáncer urotelial
#13	AnnotatorNotes T14	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
T15	DISO 763 769	lesión
#14	AnnotatorNotes T15	C0221198; Lesion; Finding
T16	PROC 968 1006	tratamiento de quimioterapia sistémica
T17	DISO 1114 1124	enfermedad
#15	AnnotatorNotes T17	C0012634; Disease; Disease or Syndrome
T18	PROC 1147 1164	tratamiento local
#16	AnnotatorNotes T18	C1517925; Local Therapy; Therapeutic or Preventive Procedure
T19	PROC 252 259	tratado
#17	AnnotatorNotes T19	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T20	DISO 1217 1238	metástasis cerebrales
#18	AnnotatorNotes T20	C0220650; Metastatic malignant neoplasm to brain; Neoplastic Process | C0555278; Cerebral metastasis; Neoplastic Process
T21	DISO 1249 1274	metástasis leptomeníngeas
#19	AnnotatorNotes T21	C1704231; Metastatic Malignant Neoplasm to the Leptomeninges; Neoplastic Process
T22	DISO 1291 1317	enfermedad autoinmunitaria
#20	AnnotatorNotes T22	C0004364; Autoimmune Diseases; Disease or Syndrome
T23	PROC 1351 1362	Tratamiento
#21	AnnotatorNotes T23	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T24	CHEM 1377 1397	anticuerpo anti-PD-1
T25	CHEM 1399 1409	anti-PD-L1
T26	CHEM 1411 1421	anti-PD-L2
T27	CHEM 1423 1433	anti-CD137
T28	CHEM 1437 1448	anti-CTLA-4
T29	CHEM 1480 1591	fármaco que se dirija específicamente a la coestimulación de los linfocitos T o a las vías del punto de control
#22	AnnotatorNotes T29	C3192215; Selective T Cell Costimulation Blocker; Pharmacologic Substance (?) | C4684977; Immune Checkpoint Inhibitors; Pharmacologic Substance (?)
T30	ANAT 1545 1557	linfocitos T
#23	AnnotatorNotes T30	C0039194; T-Lymphocyte; Cell
T31	CHEM 1467 1477	anticuerpo
#24	AnnotatorNotes T31	C0003241; Antibodies; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T32	DISO 774 792	enfermedad medible
#25	AnnotatorNotes T32	C1513041; Measurable Disease; Disease or Syndrome
T33	PROC 1704 1715	tratamiento
#26	AnnotatorNotes T33	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T34	PROC 474 481	tratado
#27	AnnotatorNotes T34	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T35	ANAT 214 223	urotelial
#28	AnnotatorNotes T35	C0227598; Urothelium; Tissue
T36	DISO 207 223	cáncer urotelial
#29	AnnotatorNotes T36	C0007138; Carcinoma, Transitional Cell; Neoplastic Process
T37	ANAT 435 444	urotelial
#30	AnnotatorNotes T37	C0227598; Urothelium; Tissue
T38	DISO 459 470	metastásico
#31	AnnotatorNotes T38	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T39	ANAT 522 531	urotelial
#32	AnnotatorNotes T39	C0227598; Urothelium; Tissue
T40	DISO 545 556	metastásico
#33	AnnotatorNotes T40	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T41	ANAT 611 620	urotelial
#34	AnnotatorNotes T41	C0227598; Urothelium; Tissue
T42	DISO 635 646	metastásico
#35	AnnotatorNotes T42	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T43	ANAT 704 713	urotelial
#36	AnnotatorNotes T43	C0227598; Urothelium; Tissue
T44	DISO 727 738	metastásico
#37	AnnotatorNotes T44	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T45	DISO 1029 1040	metastásico
#38	AnnotatorNotes T45	C0027627; Neoplasm Metastasis; Neoplastic Process | C4255448; Metastasis; Pathologic Function
T46	ANAT 1228 1238	cerebrales
#39	AnnotatorNotes T46	C0242202; Cerebrum; Body Part, Organ, or Organ Component | C1269537; Entire brain; Body Part, Organ, or Organ Component | C1280654; Entire cerebrum; Body Part, Organ, or Organ Component
T47	ANAT 1260 1274	leptomeníngeas
#40	AnnotatorNotes T47	C0228126; Leptomeninges; Body Part, Organ, or Organ Component | C1284563; Entire leptomeninges; Body Part, Organ, or Organ Component
T48	CHEM 1640 1663	vacunas vivas/atenuadas
#41	AnnotatorNotes T48	C0042211; Vaccines, Attenuated; Immunologic Factor · Pharmacologic Substance
T49	PROC 560 567	tratado
#42	AnnotatorNotes T49	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T50	PROC 650 657	tratado
#43	AnnotatorNotes T50	C0087111; Therapeutic procedure; Therapeutic or Preventive Procedure
T51	Date 13 17	2016
T52	LIVB 193 202	pacientes
#44	AnnotatorNotes T52	C0030705; Patients; Patient or Disabled Group
T53	Neg_cue 249 251	no
T54	Neg_cue 471 473	no
T55	Neg_cue 557 559	no
T56	Neg_cue 647 649	no
T58	Neg_cue 961 967	Ningún
T59	LIVB 1068 1077	Pacientes
#45	AnnotatorNotes T59	C0030705; Patients; Patient or Disabled Group
T60	LIVB 1100 1109	Pacientes
#46	AnnotatorNotes T60	C0030705; Patients; Patient or Disabled Group
T61	Spec_cue 1132 1146	susceptible de
T62	LIVB 1203 1212	Pacientes
#47	AnnotatorNotes T62	C0030705; Patients; Patient or Disabled Group
T63	LIVB 1277 1286	Pacientes
#48	AnnotatorNotes T63	C0030705; Patients; Patient or Disabled Group
T64	Spec_cue 1340 1348	sospecha
T65	Neg_cue 1615 1617	no
T67	Duration 1679 1686	30 días
T57	PHYS 1523 1557	coestimulación de los linfocitos T
#49	AnnotatorNotes T57	C1622572; T cell costimulation; Cell Function
T66	LIVB 410 423	participantes
#50	AnnotatorNotes T66	C4554048; Study Participant; Population Group
T68	LIVB 1601 1614	participantes
#51	AnnotatorNotes T68	C4554048; Study Participant; Population Group
A1	Assertion T19 Negated
A2	Assertion T34 Negated
A3	Assertion T50 Negated
A4	Assertion T16 Negated
A5	Assertion T18 Speculated
A6	Assertion T22 Speculated
A7	Assertion T48 Negated
A8	Status T34 History_of
A9	Status T49 History_of
A10	Status T50 History_of
A11	Status T16 History_of
A12	Status T22 History_of
A13	Status T23 History_of
A14	Status T24 History_of
A15	Status T25 History_of
A16	Status T26 History_of
A17	Status T27 History_of
A18	Status T28 History_of
A19	Status T31 History_of
A20	Status T29 History_of
#52	AnnotatorNotes T7	C0282461; Phase 3 Clinical Trials; Research Activity + C1709323; Open Label Study; Research Activity + C0034656; Randomization; Research Activity
#53	AnnotatorNotes T16	C1883256; Systemic Chemotherapy; Therapeutic or Preventive Procedure 
#54	AnnotatorNotes T24	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#55	AnnotatorNotes T25	C4289971; Anti-PD-L1 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
#56	AnnotatorNotes T27	C4732974; Anti-CD137 Monoclonal Antibody; Amino Acid, Peptide, or Protein · Immunologic Factor · Pharmacologic Substance
T69	Observation 854 870	capaz de caminar
#57	AnnotatorNotes T69	C2712089; Able to walk (finding); Finding
T70	Observation 873 929	llevar a cabo actividades ligeras como tareas domésticas
#58	AnnotatorNotes T70	C4534513; Performing activities of daily living; Finding (?)
T71	Observation 940 958	trabajo de oficina
#59	AnnotatorNotes T71	C2230102; working as office worker; Finding (?)
T72	Observation 800 824	tener actividad completa
R1	Overlap Arg1:T15 Arg2:T32	
T73	Quantifier_or_Qualifier 752 762	al menos 1
R2	Has_Quantifier_or_Qualifier Arg1:T15 Arg2:T73	
R3	Location_of Arg1:T43 Arg2:T14	
R4	Before Arg1:T14 Arg2:T44	
T74	Observation 714 724	inoperable
#60	AnnotatorNotes T74	C4039777; Tumor surgically unresectable; Finding
R5	Has_Quantifier_or_Qualifier Arg1:T14 Arg2:T74	
T75	Observation 532 542	inoperable
#61	AnnotatorNotes T75	C4039777; Tumor surgically unresectable; Finding
R6	Location_of Arg1:T39 Arg2:T12	
R7	Has_Quantifier_or_Qualifier Arg1:T12 Arg2:T75	
R8	Before Arg1:T12 Arg2:T40	
R9	Before Arg1:T13 Arg2:T42	
R10	Location_of Arg1:T41 Arg2:T13	
T76	Observation 621 632	irresecable
#62	AnnotatorNotes T76	C4039777; Tumor surgically unresectable; Finding
R11	Has_Quantifier_or_Qualifier Arg1:T13 Arg2:T76	
T77	Observation 445 456	irresecable
#63	AnnotatorNotes T77	C4039777; Tumor surgically unresectable; Finding
R12	Has_Quantifier_or_Qualifier Arg1:T11 Arg2:T77	
R13	Before Arg1:T11 Arg2:T38	
R14	Location_of Arg1:T37 Arg2:T11	
T78	Observation 224 234	inoperable
#64	AnnotatorNotes T78	C4039777; Tumor surgically unresectable; Finding
R15	Location_of Arg1:T35 Arg2:T36	
R16	Has_Quantifier_or_Qualifier Arg1:T36 Arg2:T78	
R17	Before Arg1:T36 Arg2:T6	
R18	Combined_with Arg1:T1 Arg2:T2	
R19	Combined_with Arg1:T1 Arg2:T3	
R20	Experiences Arg1:T52 Arg2:T1	
R21	Experiences Arg1:T52 Arg2:T4	
R22	Experiences Arg1:T52 Arg2:T36	
R24	Experiences Arg1:T52 Arg2:T6	
R25	Negation Arg1:T53 Arg2:T19	
R26	Experiences Arg1:T52 Arg2:T5	
R27	Combined_with Arg1:T8 Arg2:T9	
R28	Experiences Arg1:T66 Arg2:T8	
R29	Experiences Arg1:T66 Arg2:T10	
R30	Experiences Arg1:T66 Arg2:T11	
R32	Experiences Arg1:T66 Arg2:T38	
R33	Experiences Arg1:T66 Arg2:T34	
R34	Negation Arg1:T54 Arg2:T34	
R35	Negation Arg1:T55 Arg2:T49	
R36	Negation Arg1:T56 Arg2:T50	
R37	Negation Arg1:T58 Arg2:T16	
T79	CONC 1093 1097	ECOG
#65	AnnotatorNotes T79	C1520224; ECOG performance status; Intellectual Product
T80	Result_or_Value 1085 1088	≥ 2
R38	Has_Result_or_Value Arg1:T79 Arg2:T80	
R39	Experiences Arg1:T60 Arg2:T17	
R40	Speculation Arg1:T61 Arg2:T18	
T81	Quantifier_or_Qualifier 1178 1200	con intención curativa
R41	Has_Quantifier_or_Qualifier Arg1:T18 Arg2:T81	
A21	Assertion T81 Speculated
R42	Experiences Arg1:T60 Arg2:T18	
R43	Location_of Arg1:T46 Arg2:T20	
R44	Location_of Arg1:T47 Arg2:T21	
R45	Experiences Arg1:T62 Arg2:T20	
R46	Experiences Arg1:T62 Arg2:T21	
R47	Experiences Arg1:T63 Arg2:T22	
R48	Speculation Arg1:T64 Arg2:T22	
T82	Quantifier_or_Qualifier 1318 1324	activa
#66	AnnotatorNotes T82	C0679217; Active State; Idea or Concept
R49	Has_Quantifier_or_Qualifier Arg1:T22 Arg2:T82	
T83	Quantifier_or_Qualifier 1239 1246	activas
#67	AnnotatorNotes T83	C0679217; Active State; Idea or Concept
R50	Has_Quantifier_or_Qualifier Arg1:T20 Arg2:T83	
R51	Used_for Arg1:T24 Arg2:T23	
R52	Used_for Arg1:T25 Arg2:T23	
R53	Used_for Arg1:T26 Arg2:T23	
R54	Used_for Arg1:T27 Arg2:T23	
R55	Used_for Arg1:T28 Arg2:T23	
R56	Used_for Arg1:T31 Arg2:T23	
R57	Used_for Arg1:T29 Arg2:T23	
R58	Used_for Arg1:T30 Arg2:T57	
R59	Experiences Arg1:T68 Arg2:T48	
R60	Negation Arg1:T65 Arg2:T48	
R61	Experiences Arg1:T68 Arg2:T33	
R62	Overlap Arg1:T48 Arg2:T67	
R63	Before Arg1:T48 Arg2:T33	
T84	Quantifier_or_Qualifier 1697 1703	primer
#68	AnnotatorNotes T84	C0205435; First (number); Quantitative Concept
R64	Has_Quantifier_or_Qualifier Arg1:T33 Arg2:T84	
R23	Experiences Arg1:T52 Arg2:T19	
#69	AnnotatorNotes T28	C4289973; Anti-CTLA-4 Monoclonal Antibody; Amino Acid, Peptide, or Protein
#70	AnnotatorNotes T81	C1880198; Cure (remedy); Conceptual Entity
A22	Experiencer T60 Patient
A23	Experiencer T62 Patient
A24	Experiencer T63 Patient
A25	Experiencer T68 Patient
A26	Experiencer T52 Patient
A27	Experiencer T66 Patient
A28	Experiencer T59 Patient
